BI-3802 |
| Catalog No.GC32178 |
Le BI-3802 est un dégradeur de BCL6 très puissant et inhibe le domaine Bric-À-brac (BTB) de BCL6 avec une IC50 ≤3 nM. Le BI-3802 induit la polymérisation de BCL6 et favorise la dégradation de BCL6 en fonction de la E3 ligase SIAH1. Le BI-3802 a une activité antitumorale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2166387-65-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BI-3802 is a highly potent BCL6 degrader, inhibiting the BTB domain of BCL6, with an IC50 of ≤3 nM; BI-3802 has antitumor activity.
BI-3802 is a BCL6 inhibitor, with an IC50 of ≤3 nM. BI-3802 shows an IC50 of 43 nM for the cellular BCL6[1].
[1]. Kerres N, et al. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6. Cell Rep. 2017 Sep 19;20(12):2860-2875.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *